Screener
Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Total Assets
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Deferred tax assets | 9,284 | 6,873 |
| Long-term certificates of deposit | 28,444 | 23,516 |
| Other assets, noncurrent | 7,344 | 7,624 |
| Total assets | $199,255 | $219,763 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $1,236 | $1,335 |
| Due to related parties | 5,085 | 227 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — total assets?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — total assets of $139.24M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — total assets changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — total assets increased by 14.9% year-over-year, from $121.14M to $139.24M.
- What does gyre pharmaceuticals — total assets mean?
- This represents the total economic resources controlled by the business segment that are expected to provide future benefits. It includes tangible and intangible assets specifically utilized or held by this segment. This metric is essential for evaluating the capital intensity and asset utilization efficiency of the segment.
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude